Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 is a Novel Regulator of Cardiac Energetics and Function
批准号:
10631449
负责人:
Stavros George Drakos
金额:
$0.53万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-12-20 至 2024-11-30
关键词:
AblationAdultAnabolismAnimal GeneticsAnimal ModelBioenergeticsBiogenesisBiological AssayCardiacCardiac MyocytesCell NucleusCellsCitric Acid CycleComplexCongestive Heart FailureCrista ampullarisDataDefectDevelopmentDown-RegulationEFRACERR1 proteinEpigenetic ProcessExerciseExhibitsFatigueFeedbackFunctional disorderGene DeliveryGene ExpressionGenesGenetic ModelsGenetic TranscriptionGlobal ChangeHeartHeart DiseasesHeart failureHumanImpairmentKnock-outKnowledgeLinkLuciferasesMaintenanceMetabolicMitochondriaMitochondrial MyopathiesMusMuscleMuscular AtrophyMyocardialMyocardial dysfunctionOxidative PhosphorylationPPAR gammaPathologicPathway interactionsPatientsPhenotypePhysiologicalProductionProteinsRecoveryRegulationRegulatory PathwayReporter GenesResistanceRespirationResponse ElementsRoleSignal PathwaySkeletal MuscleStimulusStress TestsSystemTestingTimeTranscription CoactivatorWorkbasechromatin immunoprecipitationcofactordensityenergy balancefunctional adaptationheart functionheart metabolismhistone methyltransferaseinduced pluripotent stem cell derived cardiomyocytesinterdisciplinary approachknock-downnovelnovel therapeutic interventionpeerpostnatal developmentpressurepromoterresponseskeletaltherapeutic targettranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Energy metabolic reprogramming occurs in the developing and diseased hearts. Mitochondria are
responsible for coordinating cellular energy production in response to physiological and pathological
stimuli. The mitochondrial regulatory system is highly regulated by several transcription factors and
coactivators that orchestrate the expression of genes involved in mitochondrial biogenesis, maintenance,
and respiration capacity. However, the transcriptional regulatory machinery in mitochondrial
bioenergetics is complex, and it is still not completely understood how mitochondria coordinately respond
to physiological and pathological stimuli.
Perm1 (“PGC-1 and ERR regulator in muscle 1”) was recently identified in skeletal muscle, as a
novel muscle-specific protein that regulates mitochondrial oxidative capacity. Perm1 is induced by
exercise, and the increased expression of Perm1 enhances mitochondrial biogenesis, oxidative capacity,
and fatigue resistance in mouse skeletal muscle. These findings point to a new path towards
understanding mitochondrial myopathies and muscle atrophies. However, the role of Perm1 in the heart
has never been investigated. Moreover, the regulatory mechanism of Perm1 in mitochondrial function is
currently unknown. Our preliminary data suggest the significant role of Perm1 in cardiac
pathophysiology: (1) Perm1 is highly expressed in the heart and is downregulated in the mouse failing
heart and in patients with heart failure; (2) Perm1 expression is increased during differentiation and
maturation in human iPS cell-derived cardiomyocytes; (3) Perm1 knockdown in cultured cardiomyocytes
leads to reduced mitochondrial respiration capacity. Furthermore, our preliminary data suggest that
Perm1 controls mitochondrial function through the regulation of ERRα, a well-known transcription factor
that orchestrates the expression of genes in mitochondrial bioenergetics.
This application will leverage a genetic animal model and state-of-the art multisystems approach
to conceptually advance our understanding of mitochondrial bioenergetics in the heart. Specifically, this
work is expected to demonstrate that Perm1 is a critical regulator of mitochondrial biosynthesis and
energetics in the heart through the ERRα pathway. Furthermore, this study will determine if gene
delivery of Perm1 to the heart protects against mitochondrial impairment and cardiac dysfunction in the
setting of pressure-overload-induced heart failure. Conclusive evidence that Perm1 is a novel
transcriptional cofactor of the mitochondrial regulatory pathway in the heart will profoundly advance our
knowledge of cardiac metabolism, and may suggest new therapeutic approaches for heart failure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of Eccentric Cardiomyocyte Hypertrophy Secondary to Mitral Regurgitation
-
批准号:10565204
-
项目类别:
-
资助金额:$59.4万
-
财政年份:2023
-
负责人:Stavros George Drakos
-
依托单位:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
-
批准号:10547828
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
-
批准号:10730363
-
项目类别:
-
资助金额:$1.16万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
-
批准号:10523981
-
项目类别:
-
资助金额:$44.83万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Understanding Myocardial Recovery in Diabetes and Heart Failure
-
批准号:10426081
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
-
批准号:10156104
-
项目类别:
-
资助金额:$54.06万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Understanding Myocardial Recovery in Diabetes and Heart Failure
-
批准号:10595643
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Stavros George Drakos
-
依托单位:
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart Failure
-
批准号:9218590
-
项目类别:
-
资助金额:$37.8万
-
财政年份:2016
-
负责人:Stavros George Drakos
-
依托单位:
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart Failure
-
批准号:10066362
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2016
-
负责人:Stavros George Drakos
-
依托单位:
Training in Cardiovascular Research
-
批准号:10626716
-
项目类别:
-
资助金额:$46.16万
-
财政年份:1994
-
负责人:Stavros George Drakos
-
依托单位:
Training in Cardiovascular Research
-
批准号:10334100
-
项目类别:
-
资助金额:$66.29万
-
财政年份:1994
-
负责人:Stavros George Drakos
-
依托单位:
海外基金